Don't let the lower BMI fool you — lean MetALD is more dangerous. A large study of nearly 100,000 veterans found that patients with lean MetALD (metabolic liver disease plus increased alcohol intake) face a 28% higher risk of major liver complications and an 82% higher risk of all-cause mortality compared to those with nonlean MetALD. Their clinical profile looks more like alcohol-associated liver disease than classic metabolic liver disease.
Being lean doesn't mean being low-risk — at least not when it comes to MetALD. A new study published in Clinical Gastroenterology and Hepatology analyzed nearly 98,000 U.S. veterans with MetALD (metabolic dysfunction-associated steatotic liver disease combined with increased alcohol intake) and found that those with a lower BMI face significantly worse outcomes than their heavier peers.
Lean MetALD patients (BMI <25 kg/m²) were older on average, had slightly higher alcohol use scores, and showed liver enzyme patterns (higher AST than ALT) more consistent with alcohol-associated liver disease — a stark contrast to nonlean patients, who more closely resembled classic metabolic liver disease with higher rates of type 2 diabetes and cardiometabolic risk factors.
By the Numbers
Why it matters: These findings challenge the assumption that lower body weight signals lower liver disease risk. Clinicians should prioritize alcohol use disorder treatment in lean MetALD patients, who represent a distinct, high-risk subgroup requiring tailored management strategies.
